Overview

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Status:
Active, not recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or metastatic HER2-negative urothelial cancer.

Phase:

Phase 2

Details

Lead Sponsor:

RemeGen
RemeGen Co., Ltd.

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins
Trastuzumab